Business Wire

YOKOGAWA-ELECTRIC

1.12.2021 05:30:11 CET | Business Wire | Press release

Share
Yokogawa Develops Single Cellome System SS2000 for Subcellular Sampling

Yokogawa Electric Corporation (TOKYO:6841) announces that it has developed the Single Cellome™ System SS2000, a single-cell analysis solution that utilizes high-resolution images captured with a confocal microscope to automatically and accurately collect samples of specific cells and intracellular components. The SS2000 will be released in Japan, the US, and China in February 2022, with release in other markets such as Europe to follow at a later date.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211130006183/en/

Development Background

As the smallest unit of all living organisms, cells can greatly differ from one another; hence, there is a growing focus on single-cell analysis involving the isolation and handling of individual cells, as opposed to studying a population. In recent years, with improved analytical technology, it has become possible to analyze not only single cells but also specific molecules within them. Understanding the characteristics and functions of cells and mechanisms for cell development is a very effective means for clarifying the causes of diseases, preventing them, and verifying the efficacy of new drugs. This is essential for drug discovery research and the development of precision medicine and regenerative medicine.

Conventional techniques for the analysis of intracellular components have typically involved the disruption and collection of heterogeneous cell populations, which does not allow for sampling at the individual cell level, so many components cannot be collected and essential information on cell location and morphology is lost. In addition, as this sampling is done manually, throughput is low, and it is quite difficult for even experienced researchers.

Utilizing Yokogawa’s core imaging technologies that enable the real-time analysis of minute phenomena in live cells, the Single Cellome System SS2000 incorporates new technologies that automatically and accurately control sampling operations in order to support the performance of cutting-edge life science research.

Features

Yokogawa confocal microscopy technology enables the rapid, minimally invasive imaging of living cells. Based on the high-sensitivity analysis of the high-resolution 3D images, the cells are automatically and precisely sampled using precise positioning technology.

1. Optimal selection of cells or regions within cells according to set criteria

The SS2000 analyzes images of a large number of cells within a target range and classifies them by using provided criteria such as cytoplasm area and nucleus size. It then identifies which cells are suitable for analysis and determines their sampling location. Utilizing criteria such as distance from the nucleus, image analysis can even identify optimal regions within individual cells.

2. Reliable sampling of target cells and components within individual cells

The SS2000 directly samples only target cells without detachment, retaining all positional and morphology information in the culture plate. Furthermore, the utilization of high-resolution 3D images and precise positioning technology enables the selective sampling of target organelles and cytoplasm.

3. Samples can be used for a broad range of analyses

The collected cells and intracellular components can be used for a broad range of analyses, including genetic analysis and mass spectrometry. The optimum and efficient collection of target samples improves analytical sensitivity. In addition, single living cells that have been sampled can be grown in secondary cell cultures.

Hiroshi Nakao, a Yokogawa Electric vice president and head of the Life Business Headquarters, comments, "The newly developed Single Cellome System SS2000 is a solution that will play a key role in future cell research. It provides the potential to understand not only the characteristics of single cells, but also the networks and communication between cells, allowing us to ascertain pathological mechanisms. In an era where more and more people are living to the age of 100, Yokogawa will accelerate the development and provision of solutions to protect lives, health, and safety."

About Yokogawa

Yokogawa provides advanced solutions in the areas of measurement, control, and information to customers across a broad range of industries, including energy, chemicals, materials, pharmaceuticals, and food. Yokogawa addresses customer issues regarding the optimization of production, assets, and the supply chain with the effective application of digital technologies, enabling the transition to autonomous operations.
Founded in Tokyo in 1915, Yokogawa continues to work toward a sustainable society through its 17,500 employees in a global network of 119 companies spanning 61 countries.
For more information, visit www.yokogawa.com

The names of corporations, organizations, products, services and logos herein are either registered trademarks or trademarks of Yokogawa Electric Corporation or their respective holders.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 11:21:00 CEST | Press release

Poster presented at ESMO Breast Cancer 2026: Exploring health policy and real-world treatment strategies for early-stage HER2-positive breast cancer across Europe. The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrat

The AI Summit London Unveils 10th Anniversary Speaker Line-Up Featuring Global Leaders in Enterprise AI7.5.2026 10:00:00 CEST | Press release

Including Executives and Policymakers from the UK Government, NVIDIA, AWS, Tony Blair Institute, AstraZeneca and Virgin Atlantic The AI Summit London today unveiled its keynote speaker line-up for the event’s 10th anniversary edition, bringing together senior leaders, technologists and policymakers from across the globe. The 2026 programme will explore the transformative power of artificial intelligence across sectors including government, enterprise, healthcare, finance and AI infrastructure. Speakers from NVIDIA, Amazon Web Services, Virgin Atlantic, AstraZeneca, the Tony Blair Institute for Global Change and JPMorgan Chase will explore AI deployment, governance, infrastructure and customer transformation across major industries. Further, Jim Carter, Director General Commercial and Industry at the Ministry of Defence, Ollie Ilott, Interim Director General, Emerging Technology and AI, UK Government, and Sasha Rubel, Head of AI/Generative AI Policy, EMEA, Amazon Web Services will lead

MOVIVA® launch spotlight at ESGE Days 20267.5.2026 09:58:00 CEST | Press release

“Turn down the food noise” During its 175th anniversary year, Erbe Elektromedizin GmbH highlights its continued commitment to healthcare innovation with the launch of MOVIVA®, a minimally invasive solution for gastric mucosal ablation (GMA) in endoscopic obesity therapy. MOVIVA® will be the central focus of Erbe’s activities at ESGE Days in Milan, 14–16 May 2026. Physicians can explore the technology in the hands-on area and attend a dedicated symposium. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507842222/en/ How GMA with MOVIVA® works “Obesity continues to rise worldwide, and many patients still face a gap between lifestyle interventions, pharmacotherapy, and bariatric surgery. Endoscopic approaches are emerging as additional treatment options. With MOVIVA®, we aim to support physicians in bringing this innovative treatment option into clinical practice and expanding access to minimally invasive obesity therapies.”

Resilience Takes Center Stage as Europe’s LEED Community Gathers in Milan for GBCI Europe Circle 20267.5.2026 09:57:00 CEST | Press release

GBCI Europe Impact Report 2026 highlights that 53% of European real estate leaders prioritize resilience as a financial imperative. Green Business Certification Inc. Europe (GBCI), is hosting Circle 2026, the annual flagship event of the European LEED community, taking place in Milan from May 6–8 and marking its fifth anniversary. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260506692329/en/ Porta Nuova, Milan - LEED v4.1 Communities: Existing, Gold certification. Photo courtesy of COIMA. At the center of discussions is LEED v5, the latest version of the world’s most widely used green building rating system, as a bridge to EU Taxonomy alignment - a critical priority for the European market, where regulatory pressure and investor demand are accelerating the integration of certification, finance, and ESG reporting. GBCI Europe Impact Report 2026: European Real Estate Shifts from Sustainability to Risk Management As part of t

Criteo Selects Navan to Modernize Global Travel Management7.5.2026 09:00:00 CEST | Press release

Global commerce intelligence platform delivers high employee satisfaction with Navan Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced that it has been selected by Criteo, the global commerce intelligence platform, to modernize its global travel program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507251188/en/ Global commerce intelligence platform delivers high employee satisfaction with Navan Criteo set out to provide its global workforce with an easy-to-use travel booking experience that brought visibility and control to its travel spending. Prioritizing operational excellence and employee experience, Criteo selected Navan because of its extensive inventory, unified travel and payments platform, and global expertise in sustainability reporting. “We wanted to give our teams a travel tool that’s as easy to use as the apps they use in their personal lives,” said Sarah Gli

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye